Aspira Women’s Health teams up with BioReference to fight ovarian cancer

Two US biotech companies have announced a co-marketing and distribution collaboration to address ovarian cancer.

Aspira Women’s Health has collaborated with BioReference, one of the largest full service specialty laboratories in the US, to co-market and distribute Ova1Plus, Aspira’s FDA-cleared blood tests that detect the risk of ovarian malignancy in women diagnosed with a pelvic mass.

Under terms of the agreement, the sales teams of the two companies will collaborate to sell Ova1Plus to gynaecologists and other women’s healthcare providers nationwide.

The collaboration is hoped to lead to more women being appropriately triaged for surgery and improve patient outcomes.

“We are excited to formally launch our collaboration with BioReference,” said Nicole Sandford, CEO of Aspira Women’s Health.

“Providing more physicians and their patients with access to our ovarian cancer risk assessment products is a top priority for Aspira, and this strategic alliance with BioReference is a significant accelerator.

“Our two organisations are well aligned with similar goals of improving care for women. We have complementary relationships and offerings that will most certainly benefit healthcare providers and the women that they serve.

“I believe this is the start of a long-term relationship that will accelerate the adoption of Ova1Plus and provide incremental revenues at attractive margins for each company,” Sandford added.

Greg Richard, head of strategy and business development at Aspira Women’s Health, said sales professionals from each company will work collaboratively to ensure physicians understand the power of our ovarian cancer risk assessment products to expand market access and provider adoption.

Craig Allen, president and BioReference CEO, said: “We are pleased to offer Ova1Plus to physicians across the country as part of our focus on women’s health and look forward to a successful collaboration with Aspira.

“As women’s health test offerings advance, it becomes more and more imperative to offer women access to information about their health.”

Aspira Women’s Health aims to transform women’s gynaecological health with the discovery, development, and commercialisation of testing options for women of all races and ethnicities.

The company says the blood tests could reduce the falsely elevated rate by up to 50 per cent, maintain the high rate of detection for ovarian cancer risk, continue to provide confidence in low-risk results with a high negative predictive value, and increased specificity by up to 20 per cent.